The recognition came less than a year after the clinic’s launch, which is a fast turnaround for any project to gain this kind of global attention. The e-health category specifically looks for digital health projects that create real social impact, not just technical innovation for its own sake.

For Saudi Arabia’s autism community, this is a meaningful moment. Families dealing with autism often face long waiting lists, limited local specialists, and the practical challenge of getting children to in-person appointments. A virtual clinic model directly addresses those barriers.

What’s the news?

The Autism Families Association’s Autism Virtual Clinic in Saudi Arabia has been selected as a finalist at the World Summit on the Information Society (WSIS) 2026 in Geneva, in the summit’s e-health category. The WSIS is organized under the United Nations framework and is one of the most prominent global platforms recognizing technology projects that serve the public good.

• The clinic was launched less than a year before receiving this recognition
• It was selected as a finalist specifically in the e-health category
• That category focuses on digital health projects with demonstrated social impact

Why does it matter?

Getting a WSIS finalist spot is not a minor achievement. The summit draws entries from governments, NGOs, and private organizations around the world, and the e-health category is competitive. Being shortlisted puts the Autism Virtual Clinic on the same stage as some of the most ambitious digital health projects globally.

For the broader region, it signals that health technology coming out of Saudi Arabia is reaching a standard recognized beyond the Gulf. That matters for other organizations in the region building similar services, as it shows international validation is within reach.

It also puts a spotlight on a real gap in healthcare. Autism diagnosis and therapy services are stretched thin in many countries. Virtual clinics can reach families in remote areas, reduce travel burdens, and potentially cut waiting times significantly.

The context

The World Summit on the Information Society was established by the United Nations in the early 2000s to address how technology can help societies develop more equitably. Its annual prizes and finalist lists have become a benchmark for socially valuable tech projects worldwide.

Saudi Arabia has been investing heavily in digital health as part of its Vision 2030 program, which aims to modernize the country’s economy and public services. Digital health is one of the areas where that investment is starting to show concrete results internationally.

Autism support specifically has been underserved by digital health innovation compared to other conditions. Most telehealth expansion over the past five years has focused on general practice or mental health for adults. Platforms built specifically around autism, covering everything from early screening to therapy support, are still relatively rare, which may be part of why this clinic stood out to judges.

The post Saudi Arabia’s autism virtual clinic wins global recognition at Geneva summit appeared first on DH Arab.

The initiative covers a wide range of technology categories, from artificial intelligence and the Internet of Things to biotechnology and 3D printing. A supervisory committee reviews each proposed solution and provides technical and regulatory guidance to help teams refine their products and prepare them for real-world use.

The ministry says the program is part of its broader push to position Saudi Arabia as a regional and global center for health innovation and advanced medical technology, in line with the goals of Vision 2030.

How does it work?

The Sandbox program gives innovators access to a controlled testing environment where they can run pilot projects without the usual regulatory barriers that would apply to a commercial launch. The process works roughly like this:

• Applicants submit their digital health solution to the program
• A supervisory committee evaluates the proposal and offers technical and regulatory guidance
• Approved solutions are tested in a pilot environment under real-world conditions
• Solutions that pass performance validation move forward to implementation

The fields covered include digital health platforms, AI-powered tools, IoT devices, biotechnology applications, and 3D printing for medical use. That breadth means the program is not limited to software, it also applies to physical medical products and hardware.

Why does it matter?

Regulatory uncertainty is one of the biggest obstacles for health tech startups anywhere in the world. Getting a product approved for clinical or commercial use typically takes years and significant legal resources. Programs like Sandbox are designed to reduce that friction by letting companies prove their technology works before they face the full weight of the approval process.

The 25 solutions that have moved to implementation represent real products now in use within the Saudi healthcare system. That is a meaningful number for a program still in relatively early stages, and it signals that the ministry is treating this as more than a showcase exercise.

The context

The Sandbox initiative sits within the Health Sector Transformation Program, one of several reform agendas operating under Saudi Vision 2030, the kingdom’s long-term plan to reduce its economic dependence on oil and modernize key public services.

Saudi Arabia has been investing heavily in health technology over the past several years, both through government programs and by attracting international companies to set up regional operations in Riyadh. The country is competing directly with the UAE, which has built a strong reputation for health tech investment through initiatives based in Dubai and Abu Dhabi.

Sandbox-style regulatory programs are increasingly common in healthcare globally. The UK’s Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration both run similar schemes to help innovators test products in controlled conditions. Saudi Arabia’s version appears to be gaining traction, with the total number of supported solutions now past 300.

The post Saudi Arabia’s health ministry has backed 342 digital health innovations through its Sandbox program appeared first on DH Arab.

The center will focus on rare metabolic, nephrological, and hematologic disorders, bringing together clinicians, researchers, and industry partners under one roof. The goal is to build a full care pathway: from early diagnosis to treatment, long-term follow-up, and research.

This is not a new idea from scratch. DoH and AstraZeneca had already signed a partnership agreement at BIO 2024 to explore this type of center. The new agreement brings PureHealth into the mix to actually run it, turning a plan into an operational commitment.

How will it work?

The three organizations will split responsibilities based on what each does best. AstraZeneca brings scientific expertise and global experience in rare disease management. PureHealth, which operates a wide network of hospitals and clinics across the UAE, will handle the operational side. DoH will provide regulatory oversight and strategic direction.

Under the MoU, the partners have agreed to work together across six main areas:

• Running the center as a dedicated hub for rare disease care
• Building an integrated model that covers diagnosis, treatment, and lifelong patient management
• Making sure patients have consistent access to specialized services
• Advancing research, clinical trials, and real-world evidence collection
• Training local clinicians and building specialized expertise in the UAE
• Setting up a shared governance framework to track progress and maintain accountability

The center will also connect to the Emirati Genome Program, Abu Dhabi’s national genomics initiative, which could play an important role in faster and more accurate diagnosis of rare genetic conditions.

Why does it matter?

Rare diseases are often called “orphan” conditions because they affect small numbers of people and tend to receive less research funding and clinical attention than more common illnesses. But the term “rare” is misleading at scale. There are thousands of rare diseases, and collectively they affect hundreds of millions of people worldwide. For each patient and their family, the impact can be severe and the path to diagnosis long and frustrating.

Sameh El Fangary, Gulf Country President at AstraZeneca, put it plainly: “Rare diseases may be overlooked as it affects a relatively small number of people, but for each of those patients and their families, the impact is devastating, and collectively the impact on the society is profound.”

For the UAE specifically, having a dedicated center matters for several reasons:

• Patients currently may need to travel abroad for specialized diagnosis or treatment
• A local center means faster access to care and better continuity for long-term conditions
• It builds clinical expertise inside the country rather than relying on imported knowledge
• Research conducted locally can generate data more relevant to the region’s patient population

The context

Abu Dhabi has been building its life sciences sector steadily over the past several years. The emirate has invested in genomics, attracted global pharmaceutical partnerships, and positioned itself as a regional hub for medical research and innovation. This rare disease center fits that broader strategy.

The BIO International Convention, where this MoU was signed, is one of the biggest gatherings in the global biotech and life sciences industry. Abu Dhabi announcing this deal there is a deliberate signal to the international research and pharma community that the emirate is open and ready for serious scientific collaboration.

PureHealth’s involvement is also worth noting. As one of the largest healthcare operators in the UAE, its participation means the center has a realistic path to actually reaching patients at scale, not just functioning as a research facility or showpiece partnership. Whether the center delivers on its ambitions will depend on how quickly the operational model takes shape and how well the three very different organizations work together day to day.

The post Abu Dhabi is building a rare disease center with AstraZeneca and PureHealth appeared first on DH Arab.

More than 40 senior representatives made the trip, drawn from 16 organizations across government, healthcare, research, and industry. The list included Abu Dhabi Investment Office, M42, Hub71, NYU Abu Dhabi, Masdar City, Khalifa University, PureHealth, and Mubadala Bio, among others.

The deals span a wide range of areas, from genomics and AI-enabled drug discovery to biomanufacturing, gene therapy, and eye banking. Taken together, they point to a clear ambition: turn Abu Dhabi into a place where new medical technologies can be developed, tested, and deployed at scale, without having to cross multiple jurisdictions to do it.

What’s the news?

The headline agreements from the mission cover several distinct areas:

• Precision medicine: The Department of Health signed collaborations with Boehringer Ingelheim, Novartis, and Eli Lilly to advance research into the genetic drivers of disease, expand AI-powered genomics work, and push forward innovation in obesity and Alzheimer’s treatment.
• Virtual human twins: M42 announced a partnership between Abu Dhabi Biobank and BioTwin to bring Virtual Human Twin technology to the UAE, which creates digital models of individual patients to simulate how they might respond to treatment.
• Biotech infrastructure: Masdar City, M42, and Attentive Science launched Biosphere Labs, a new facility designed to speed up biotechnology research and commercialization.
• Clinical trials: Hub71 startup BioSapien advanced to Phase 1 clinical trials, an early but meaningful sign that Abu Dhabi can support biotech companies from early-stage innovation through to human testing.
• Biomanufacturing: Mubadala Bio signed an agreement with Biosidus to manufacture biologic medicines locally, reducing the region’s dependence on imported therapies.
• Eye banking: Abu Dhabi Biobank and Bascom Palmer Eye Institute announced plans to establish the Middle East’s first eye bank in Abu Dhabi, which will support transplantation, reduce reliance on donor tissue from abroad, and anchor a new center for ophthalmic research.
• California corridor: The Department of Health partnered with Biocom California to create a formal life sciences link between Abu Dhabi and California, opening channels for research collaboration, investment, and commercialization between the two regions.

Why does it matter?

The scale and variety of these agreements reflect something more than routine diplomatic activity. Abu Dhabi is trying to build the kind of end-to-end life sciences environment that typically only exists across multiple countries or institutions. The goal is to have genomics data, AI infrastructure, clinical research capacity, regulatory frameworks, and manufacturing all operating in one place.

That matters because the biggest bottleneck in modern medicine is rarely the science itself. It’s the distance between a discovery and its use in a real patient. Moving a new therapy from a lab result to a clinical trial to regulatory approval to actual treatment can take over a decade, partly because each of those steps happens in a different place, under different rules, with different funding. Abu Dhabi is betting that collapsing that process into a single ecosystem will attract the companies and researchers who are tired of fighting that friction.

The Bascom Palmer eye bank deal is a good example of why this approach can deliver concrete results. Bascom Palmer is consistently ranked among the top ophthalmology programs in the world. Anchoring that kind of institution in Abu Dhabi doesn’t just serve local patients; it positions the emirate as a regional reference point for a specific area of medicine, with the research output and clinical expertise that follows from that.

The context

Abu Dhabi has been building toward this position for several years. The HELM Cluster, run by Abu Dhabi Investment Office, is the main organizing structure for the emirate’s health and life sciences investment strategy. HELM connects researchers, investors, companies, and healthcare providers under one framework, and the US mission was partly a showcase for what that cluster can offer international partners.

The broader backdrop is a global race among emerging life sciences hubs. Singapore, Saudi Arabia, and several European cities are all competing to attract pharmaceutical investment, clinical research, and biotech startups. Abu Dhabi’s pitch is built on a few specific advantages:

• A large, relatively young population with high rates of conditions like diabetes and obesity, which makes it a useful place to run trials for metabolic disease treatments
• A national genomics program through Abu Dhabi Biobank that gives researchers access to population-level genetic data
• A regulatory environment that, by regional standards, moves quickly
• Significant sovereign wealth and investment capacity through vehicles like Mubadala

California is a deliberate choice of partner. The San Francisco Bay Area and San Diego are two of the most concentrated life sciences regions in the world, home to hundreds of biotech companies, major university research programs, and deep pools of venture capital. A formal corridor between Abu Dhabi and California gives companies in both places a structured way to explore markets, talent, and funding on the other side of the world.

Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health, framed the mission’s purpose clearly: “The future of life sciences will not be defined by discovery alone, but by how quickly discovery can be translated into meaningful impact for people and communities.” That framing, speed of translation rather than scientific priority, is central to how Abu Dhabi is positioning itself relative to more established research centers.

The post Abu Dhabi locks in 22 partnerships on US life sciences tour appeared first on DH Arab.

The centerpiece is the AI Adoption Barometer, developed through startAD’s AI for Good initiative with funding from Google.org. It is the first report of its kind to capture how UAE organizations in these two sectors are actually approaching AI adoption, based on input from 52 organizations. The picture it paints is one of real enthusiasm running ahead of real readiness.

Alongside the report, startAD has released two hands-on playbooks and a new resource hub, all designed for teams without deep technical backgrounds. The goal is to give organizations a clear, step-by-step path from “we should probably look at AI” to “we have a working pilot.”

How does it work?

The AI Adoption Barometer is a benchmarking tool. Organizations can download it, compare their own situation against the survey findings, and use it to inform decisions about where to invest time and resources. It covers the key challenges organizations face, including:

• Identifying which AI use cases are actually worth pursuing
• Setting up governance so AI is used responsibly
• Allocating budgets when AI is competing with other priorities
• Measuring whether AI is actually making a difference
• Scaling what works beyond a single pilot project

The two playbooks are designed to be used in sequence. The AI Use Case Discovery Playbook helps a team go from a vague idea to a clearly defined, testable use case. No technical knowledge required. The Evaluate and Pilot AI Solutions Playbook then walks teams through picking the right solution and running a responsible pilot inside their existing operations.

Both playbooks, plus the Barometer, are available through the new startAD AI Resource Hub.

Why does it matter?

The numbers in the Barometer reveal a specific kind of problem. In healthcare, 81% of surveyed organizations have defined AI use cases, and 58% are already running pilots or deployments. That sounds promising. But 42% of those same organizations have no dedicated AI budget at all. Momentum without money is a fragile thing.

In the social impact sector, the challenge is more basic. Many organizations are still trying to figure out what AI could actually do for them, let alone how to fund or run a pilot.

Ashwin Joshi, Director of startAD, put it plainly: “One of the clearest needs that emerged from our work was for practical, step-by-step implementable, accessible guidance, tools that meet organizations where they are and help them move forward responsibly and realistically.”

Anthony Nakache, Managing Director of Google MENA, made a point worth noting: “This project challenges the assumption that meaningful AI requires massive financial resources or specialized technical proficiency.” Google.org’s support is specifically aimed at improving healthcare access for disadvantaged communities across the UAE.

The context

The AI for Good program has been running for some time before this launch. To date it has worked with five organizations across 13 AI readiness workshops, recorded a 43% overall increase in AI readiness among participants, and brought in close to 200 university students and solution builders from the UAE, Saudi Arabia, and the wider MENA region.

This launch comes as AI adoption in the Middle East is accelerating fast, driven by government investment, large-scale infrastructure projects, and a growing number of tech partnerships between global companies and regional institutions. But most of the attention and resources tend to go to large enterprises and government entities. Healthcare providers and nonprofits, which often have the most to gain from AI tools, are routinely left behind because they lack the in-house expertise to evaluate options and run pilots safely.

Tools like these playbooks are a direct response to that gap. The broader trend across the AI industry right now is a shift away from big announcements toward practical implementation, and that shift is happening faster in some sectors than others. For mission-driven organizations in the UAE, this resource hub is one of the more concrete attempts to bring them into that conversation.

The post StartAD launches AI adoption barometer to help UAE healthcare and social impact organizations move past the hype appeared first on DH Arab.

The procedure is the first completed under the hospital’s newly launched Stem Cell Transplantation and Cellular Therapy Program. Until now, this type of treatment was only available through public sector hospitals in Saudi Arabia.

Dr. Mazen Fakeeh, President of Fakeeh Care Group, called it a significant step in the group’s push toward expanding specialized medical services, and a sign of the private sector’s growing role in delivering complex care across the country.

How did it go?

The transplant used the patient’s own stem cells, which is what “autologous” means in this context. The process works in three stages:

• Stem cells are collected from the patient after an initial round of treatment
• High-dose chemotherapy is given to destroy as many cancer cells as possible
• The stored stem cells are reinfused to rebuild bone marrow function and restart healthy blood cell production

Dr. Ahmed Alsaeed, a hematology and bone marrow transplantation consultant at the hospital, said the successful outcome reflects the institution’s clinical expertise and the infrastructure it has built to support this kind of procedure at international standards.

Why does it matter?

For patients with multiple myeloma who qualify for this treatment, access has historically meant going through the public system or traveling abroad. Having a private hospital capable of performing the procedure changes that.

It also signals a broader shift. Saudi Arabia’s Vision 2030 health reforms are pushing for greater private sector involvement in specialized care, and this transplant is a concrete example of that policy translating into clinical practice. When more providers can offer complex treatments locally, patients spend less time waiting and less money traveling.

Autologous stem cell transplantation is considered a standard treatment option for eligible multiple myeloma patients because it can produce deeper responses than chemotherapy alone, extend the period before the disease progresses, and improve quality of life.

The context

Dr. Soliman Fakeeh Hospital’s oncology center already offers a wide range of cancer treatments, including robotic-assisted surgery, immunotherapy, targeted therapy, and radiation. Cases are reviewed by a tumor board, a multidisciplinary team that builds individualized treatment plans for each patient.

Multiple myeloma is the second most common blood cancer globally. It is not curable in most cases, but modern treatment, including stem cell transplantation, has significantly extended survival over the past two decades. The global stem cell therapy market has grown rapidly as more conditions become treatable through cellular approaches, and hospitals across the Middle East have been investing in the infrastructure needed to offer these therapies locally rather than referring patients overseas.

This transplant puts Dr. Soliman Fakeeh Hospital among a small group of private institutions in the region with verified in-house capability for bone marrow transplantation, a milestone that will likely increase pressure on other private providers to build similar programs.

The post Dr. Soliman Fakeeh Hospital completes Saudi Arabia’s first private-sector stem cell transplant appeared first on DH Arab.

CHG operates more than 700 beds across six facilities in the UAE and Saudi Arabia, employing over 1,200 healthcare professionals. It is majority-owned by Amanat Holdings PJSC and holds accreditations from bodies including Joint Commission International and the Commission on Accreditation of Rehabilitation Facilities. Middlesex University Dubai is part of the London-based Middlesex University network and has a significant presence in Dubai Knowledge Park.

The agreement sets out a broad agenda covering research, digital health, professional training and community wellbeing. While MOUs are non-binding in nature, this one is detailed enough to signal serious intent from both sides, with five named strategic pillars and a plan to build joint Centres of Excellence.

How will it work?

The partnership is built around five areas of collaboration:

• Research: Joint projects on health economics, rehabilitation and integrated care, with shared grant applications, publications and conferences.
• Digital health and AI: Work on predictive analytics, remote patient monitoring and healthcare data analytics to improve patient outcomes.
• Workforce development: Graduate career programmes, internships, industry placements and customised executive education for healthcare professionals.
• Centres of Excellence: Plans to build dedicated centres focused on post-acute care, rehabilitation, digital health, AI, predictive home care, and dementia and healthy ageing.
• Community health: Joint wellbeing programmes, academic exchanges and industry advisory work aimed at strengthening healthcare systems beyond the hospital setting.

Wael K. Abdallah, Group CEO of Cambridge Health Group, said the deal would “advance innovation in post-acute care, rehabilitation and digital health while creating meaningful opportunities for professional development, knowledge creation and improved patient care.”

Professor Cedwyn Fernandes, Provost and Director of Middlesex University Dubai, framed it as a way to “develop solutions that improve healthcare delivery while preparing the next generation of healthcare professionals.”

Why does it matter?

Post-acute care, which covers rehabilitation, long-term care and home healthcare after a hospital stay, is a growing but often underfunded area of healthcare globally. In the Gulf region, it is still developing relative to the acute hospital sector, which makes research partnerships like this one genuinely useful rather than purely symbolic.

The focus on AI and digital health is also worth noting. Predictive analytics and remote monitoring are already changing how chronic and long-term conditions are managed in more mature healthcare markets. Applying that kind of thinking to the UAE and Saudi Arabia, where the patient population and healthcare infrastructure are both growing fast, could produce practical results.

For MDX Dubai, the deal gives students direct access to a major clinical network for placements and applied research. For CHG, it provides an academic partner to help build credibility around research output and workforce training at a time when competition for qualified healthcare professionals in the region is intense.

The context

Both the UAE and Saudi Arabia have made healthcare development a national priority. Saudi Vision 2030 includes significant investment in health infrastructure and localisation of the healthcare workforce. The UAE has similar ambitions, with Dubai and Abu Dhabi both investing in health tech and medical education.

Middlesex University Dubai has been active on the AI front recently. Just days before this announcement, the university said it had trained more than 100 staff members in AI applications for their day-to-day roles, a sign that the institution is trying to build genuine capability rather than just talk about the technology.

CHG’s parent company, Amanat Holdings, is a healthcare and education investment company listed on the Abu Dhabi Securities Exchange. Its backing gives CHG both the financial stability and the strategic incentive to invest in partnerships that link clinical operations to education and research, which is increasingly how the most competitive healthcare groups in the region are positioning themselves.

The post Cambridge Health Group and Middlesex University Dubai sign healthcare education deal appeared first on DH Arab.

The company has launched a B2B digital marketplace specifically built for the GCC healthcare sector. It brings together medical equipment suppliers, clinics, service providers, logistics companies, and investors in one place, letting them search, connect, and transact directly. The goal is to cut down the time and friction involved in doing business across a market that has, until now, lacked a central hub.

The timing is notable. The GCC healthcare market is currently valued at around $33 billion and is projected to reach roughly $60 billion by 2030. That kind of growth creates real demand for better commercial infrastructure, and MedSahra is positioning itself to build it.

How does it work?

MedSahra is a marketplace, but not just for products. It covers a wider range of commercial activity than a typical equipment exchange. On the platform, users can:

• Buy and sell new and pre-owned medical equipment
• Find and connect with business and technical partners
• Access specialized professional services
• Explore investment and acquisition opportunities
• Coordinate logistics across the region

The platform uses intelligent matching to help users find relevant connections faster, rather than relying on manual searches or cold outreach. Listings are moderated, and users can go through an optional verification process, which MedSahra says adds a layer of trust to transactions. Once matched, parties can communicate and negotiate directly within the platform.

Co-founder Boris Shleyfer described the problem plainly: “Many businesses still depend on fragmented channels to find and sell medical equipment, provide business services, partners and investment opportunities. MedSahra was built to give professional market participants a more structured way to transact with confidence.”

Why does it matter?

The fragmentation problem in GCC healthcare commerce is real, and it costs businesses time and money. Right now, a clinic looking to sell used equipment, source a new supplier, and find a technology partner might need to use three different channels, rely on personal introductions, or attend trade events just to make the right connections. That’s inefficient at any scale, and it becomes a bigger problem as the market grows.

Co-founder Iuliia Belokrinitskaia put it this way: “Healthcare is no longer driven by providers alone. It depends on a connected business ecosystem, where every decision relies on trusted partners, market visibility and efficient collaboration. Today, those connections remain fragmented across the GCC.”

What MedSahra is building isn’t just a directory. The combination of verified listings, direct communication, and transaction support means it’s trying to replace a process, not just a search engine. If it works, it could meaningfully reduce the time and cost involved in commercial healthcare decisions across the region.

The context

The GCC has been investing heavily in healthcare infrastructure for years, driven by growing populations, government diversification goals, and increased demand for specialized care. Saudi Arabia’s Vision 2030, for example, includes significant commitments to expanding the private healthcare sector and attracting foreign investment. Similar initiatives exist across the UAE, Qatar, and Kuwait.

Despite that investment, the commercial layer of healthcare, meaning the supply chains, service networks, and business partnerships that support clinical operations, has lagged behind. Most marketplaces serving the region are either too broad (general B2B platforms not built for healthcare) or too narrow (single-category equipment sites).

MedSahra is one of the first platforms to target the full ecosystem rather than one piece of it. Whether it can build the trust and critical mass needed to become the default marketplace for GCC healthcare commerce is still an open question, but the market gap it’s addressing is clear, and the timing, given projected growth through 2030, is hard to argue with.

The post MedSahra launches B2B platform to connect GCC’s fragmented healthcare market appeared first on DH Arab.

The partnership connects one of the world’s most respected cancer research institutions with Abu Dhabi’s growing life sciences infrastructure. On the MIT side, the Koch Institute has long operated at the intersection of biology and technology, bringing together cancer biologists, engineers, and clinicians under one roof. On the Abu Dhabi side, the DoH oversees the emirate’s entire healthcare sector and has been actively working to position the UAE as a regional hub for medical innovation.

The deal aligns with the UAE’s National Cancer Strategy and covers research, talent development, and startup support – making it broader in scope than a typical academic research agreement.

How will it work?

The collaboration has three main areas of focus. First, the research side:

• Large-scale, multi-institutional clinical trials and translational research studies
• Shared research databases and biobanks built specifically for population-level cancer research
• Participation in MIT’s Bioconvergence Cancer Alliance, a network of institutions working on next-generation cancer science

A particular emphasis will be placed on cancer challenges linked to climate and population-specific factors – a nod to the Gulf region’s unique environmental conditions and genetic profiles, which are often underrepresented in global cancer research datasets.

Second, talent development. The two institutions plan to set up physician-scientist fellowships, bilateral exchange programs, and joint learning opportunities. The goal is to train healthcare professionals in clinical oncology, AI, and computational biology.

Third, a bioconvergence incubator will be established to support early-stage startups working at the intersection of AI and oncology. Founders will get access to mentorship, scientific expertise, and connections to investors.

Why does it matter?

Cancer is the second leading cause of death globally, and the Middle East faces a growing burden from the disease. Rates of certain cancers in the Gulf region have been rising, partly due to lifestyle factors and partly because the population is aging. Yet most major cancer research has historically focused on Western populations, leaving significant gaps in our understanding of how cancer behaves differently across ethnic and genetic groups.

Building shared biobanks and running population-specific research studies could help close that gap – and potentially produce findings that benefit patients far beyond the UAE.

There is also a talent angle. The Gulf region has historically sent its brightest medical and scientific minds abroad for advanced training, with no guarantee they return. Structured fellowships and exchange programs tied to a prestigious institution like MIT could help Abu Dhabi retain and attract top scientific talent.

H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the DoH, framed the partnership around real-world impact: “We define innovation by the impact it creates at a population-level. Together, we will advance new approaches to cancer research, talent development and bioconvergence innovation while creating new opportunities to build, test and scale solutions that can benefit patients in Abu Dhabi and around the world.”

The context

This announcement fits into a broader pattern. Gulf states, led by the UAE and Saudi Arabia, have been investing heavily in life sciences and health tech over the past several years. Abu Dhabi in particular has been building out its healthcare innovation infrastructure, attracting international institutions and creating incentives for biotech companies to set up in the emirate.

MIT, for its part, has been expanding its global research partnerships. The Koch Institute already works with industry partners and academic institutions around the world through its alliance model, so adding Abu Dhabi is consistent with that strategy.

Matthew Vander Heiden, Director of the MIT Koch Institute, said the collaboration reflects a belief that solving complex health problems requires working across disciplines and geographies: “We look forward to connecting MIT’s research community with Abu Dhabi’s growing healthcare innovation ecosystem, to exploring together new opportunities in oncology, AI and precision medicine.”

What makes this deal worth watching is the combination of elements: serious research infrastructure, a talent pipeline, and a startup incubator, all tied to a specific scientific mission. Whether it produces results will depend on execution – but the structure is more concrete than many high-profile international research announcements tend to be.

The post Abu Dhabi health authority teams up with MIT’s cancer research institute on AI-driven oncology appeared first on DH Arab.

The agreement covers Egypt, the United Arab Emirates, Saudi Arabia, Kuwait, and Iraq. It gives Health Arena exclusive sales rights for VUNO’s HATIV P30, a six-lead portable ECG device that uses AI to read heart data quickly and accurately. The deal was announced at CardioAlex, the largest cardiology conference in the Middle East and Africa, held in Alexandria, Egypt, in mid-June.

Around the same time, VUNO was also exhibiting in Thailand at the 38th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) conference, where it promoted a second AI product aimed at detecting eye disease. The back-to-back appearances signal a clear push to build a foothold across two fast-growing healthcare markets.

How does it work?

VUNO makes AI software that helps doctors interpret medical images and data. The two products on show at these conferences do quite different things:

• HATIV P30 is a portable device that records a six-lead ECG. It is designed to be simple enough for use outside of hospitals, where trained cardiologists may not be available. The AI analyses the reading and flags abnormalities.
• VUNO Med-Fundus AI analyses photographs of the back of the eye (the fundus) and checks for signs of 12 different conditions. Research has shown it helps reduce inconsistencies that occur when staff with different levels of experience interpret the same images.

Both products have regulatory clearance in multiple markets. HATIV P30 holds approvals from the EU (CE-MDR), the UK (UKCA), Egypt, and Indonesia, which helped the company demonstrate credibility to local officials at CardioAlex.

Why does it matter?

This deal marks VUNO’s first actual export result in the Middle East, which the company describes as a meaningful step rather than just a commercial agreement. The region has been expanding telemedicine services, and there is growing demand for tools that can bring decent diagnostic capability to areas with limited specialist coverage.

The same logic applies in Southeast Asia. At APACRS, VUNO and its Thai partner Hollywood International focused attention on public hospitals and clinics in Thailand that do not have ophthalmologists on staff. An AI tool that can read eye scans without a specialist present addresses a real gap in those settings.

For VUNO, these two regions represent different but connected opportunities:

• The Middle East deal gives the company a structured sales channel across five countries in one agreement.
• Southeast Asia offers a longer-term market entry play, starting with Thailand and potentially spreading to other countries in the region.
• Both markets could also feed into VUNO’s stated goal of expanding into Europe and the wider Middle East with its eye-disease product.

The context

VUNO is listed on South Korea’s KOSDAQ exchange (338220.KQ) and has been working to grow its revenue base outside Korea. Like many Korean medical AI companies, it has solid domestic clinical evidence but needs international regulatory approvals and local distribution partners to scale. The five-country Middle East agreement is a clear attempt to solve both problems at once.

The broader medical AI sector is seeing more deals of this type, where technology companies from Asia pair with regional distributors rather than trying to build their own sales teams from scratch. It is a faster route to market, though it does mean sharing margin and depending on a partner’s existing relationships.

VUNO CEO Lee Ye-ha said the conferences confirmed strong local interest in the company’s products and that the Middle East result would help the company speed up its push into global markets.

The post VUNO signs five-country Middle East deal for its AI heart monitor appeared first on DH Arab.